相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function
Kui S. Voo et al.
JOURNAL OF IMMUNOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Glucocorticoid-Induced Tumor Necrosis Factor Receptor Family-Related Ligand Triggering Upregulates Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1 and Promotes Leukocyte Adhesion
Pedro Miguel Lacal et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
De-Gang Song et al.
BLOOD (2012)
Pharmacological modulation of GITRL/GITR system: therapeutic perspectives
Giuseppe Nocentini et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory
Jang-June Park et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis
Kendra Garrison et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
Julien Fourcade et al.
CANCER RESEARCH (2012)
CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
Christina Claus et al.
CANCER RESEARCH (2012)
Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
Inge Verbrugge et al.
CANCER RESEARCH (2012)
Modulation of GITR for cancer immunotherapy
David A. Schaer et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression
Christian Schuerch et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
被撤回的出版物: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Immunotherapy of Cancer with 4-1BB
Dass S. Vinay et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage et al.
NATURE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression
William L. Redmond et al.
PLOS ONE (2012)
4-1BB signaling beyond T cells
Dass S. Vinay et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2011)
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells
Scott K. Pruitt et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Science gone translational: the OX40 agonist story
Andrew D. Weinberg et al.
IMMUNOLOGICAL REVIEWS (2011)
Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy
Juan Dubrot et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function
Jessica Ann Hernandez-Chacon et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Role of CD27/CD70 pathway of activation in immunity and tolerance
Julie Denoeud et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Combinatorial Therapy for Liver Metastatic Colon Cancer: Dendritic Cell Vaccine and Low-Dose Agonistic Anti-4-1BB Antibody Co-Stimulatory Signal
Hyunah Lee et al.
JOURNAL OF SURGICAL RESEARCH (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
Michael A. Curran et al.
PLOS ONE (2011)
Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope
David A. Schaer et al.
PLOS ONE (2011)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
Michael Croft
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, and T Cell Subsets within the Established Tumor Microenvironment
Angela D. Pardee et al.
CANCER RESEARCH (2010)
Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis
K-John J. Cheung et al.
CANCER RESEARCH (2010)
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
Jun Mitsui et al.
CLINICAL CANCER RESEARCH (2010)
A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2
Silvia Piconese et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Combination of Adoptive Cell Transfer and Antibody Injection Can Eradicate Established Tumors in Mice-An in vivo study using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb-
Akira Watanabe et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2010)
BTLA mediates inhibition of human tumor-specific CD8(+) T cells that can be partially reversed by vaccination
Laurent Derre et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production
Victor Peperzak et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
OX40 is required for regulatory T cell-mediated control of colitis
Thibault Griseri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
Kazuyoshi Takeda et al.
JOURNAL OF IMMUNOLOGY (2010)
Combining T-cell Vaccination and Application of Agonistic Anti-GITR mAb (DTA-1) Induces Complete Eradication of HPV Oncogene Expressing Tumors in Mice
Corinna Hoffmann et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice
Michael J. Gough et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice
Gloria H. Y. Lin et al.
PLOS ONE (2010)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Adam D. Cohen et al.
PLOS ONE (2010)
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Paolo A. Ascierto et al.
SEMINARS IN ONCOLOGY (2010)
Signaling Through OX40 Enhances Antitumor Immunity
Shawn M. Jensen et al.
SEMINARS IN ONCOLOGY (2010)
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
Roch Houot et al.
BLOOD (2009)
Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy
D. Boczkowski et al.
CANCER GENE THERAPY (2009)
Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression
Naoko Imai et al.
CANCER SCIENCE (2009)
The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation
Guifang Cai et al.
IMMUNOLOGICAL REVIEWS (2009)
Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours
Jinhua Piao et al.
IMMUNOLOGY (2009)
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
Daniel Hirschhorn-Cymerman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right
Carl E. Ruby et al.
JOURNAL OF IMMUNOLOGY (2009)
The role of TNF superfamily members in T-cell function and diseases
Michael Croft
NATURE REVIEWS IMMUNOLOGY (2009)
Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling
Hiroyoshi Nishikawa et al.
CANCER RESEARCH (2008)
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
Raanan Berger et al.
CLINICAL CANCER RESEARCH (2008)
Structural basis for ligand-mediated mouse GITR activation
Zhaocai Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Evolution of GITRL immune function: Murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily
Kausik Chattopadhyay et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions
Katrin M. Baltz et al.
FASEB JOURNAL (2007)
Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain
Nicholas P. Morris et al.
MOLECULAR IMMUNOLOGY (2007)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Agonist anti-GITR antibody enhances vaccine-induced CD8+ T-cell responses and tumor immunity
AD Cohen et al.
CANCER RESEARCH (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Eradication of established tumors in mice by a combination antibody-based therapy
Tomoyasu Uno et al.
NATURE MEDICINE (2006)
Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity
T So et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K Ko et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia
CR Ruprecht et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity:: a novel regulatory role for OX40 and its comparison with GITR
B Valzasina et al.
BLOOD (2005)
Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-XL and c-FLIPshort via phosphatidylinositol 3-kinase and AKT/protein kinase B
L Stärck et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells
I Takeda et al.
JOURNAL OF IMMUNOLOGY (2004)
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
MJ Turk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+ CD25+ T cells
GL Stephens et al.
JOURNAL OF IMMUNOLOGY (2004)
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1
HW Lee et al.
JOURNAL OF IMMUNOLOGY (2002)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases
PY Pan et al.
MOLECULAR THERAPY (2002)
Cutting edge: expression of functional CD137 receptor by dendritic cells
RA Wilcox et al.
JOURNAL OF IMMUNOLOGY (2002)
Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance
J Shimizu et al.
NATURE IMMUNOLOGY (2002)
CD4+CD25+ immunoregulatory T cells:: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor
RS McHugh et al.
IMMUNITY (2002)
The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity
Y Morel et al.
JOURNAL OF IMMUNOLOGY (2001)
CD27 is required for generation and long-term maintenance of T cell immunity
J Hendriks et al.
NATURE IMMUNOLOGY (2000)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice
MS Sabel et al.
JOURNAL OF IMMUNOTHERAPY (2000)
Engagement of the OX-40 receptor in vivo enhances antitumor immunity
AD Weinberg et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
